Literature DB >> 10716062

Overview of stobadine bioanalysis: evaluation and application in pharmacokinetics.

K Bauerová1.   

Abstract

Besides its many pharmacodynamic actions, the pyridoindole stobadine was found to exert antioxidant activity and thus possesses the potential to protect various tissues against oxidative stress. This overview is focussed on both the evaluation of the chemical procedures used in the bioassay of stobadine and its metabolites and on the comparison of their quality in the light of applicability for preclinical and clinical pharmacokinetic experiments. All methods and applications were performed at the Institute of Experimental Pharmacology, SASc in Bratislava, Slovakia. In pharmacokinetic and toxicokinetic studies, [3H]-labeled stobadine dihydrochloride was administered intravenously or orally to rats in single and repeated doses. Liquid-liquid extraction was used for selective isolation of stobadine and its metabolites from biological matrix, followed by liquid scintillation quantification. A TLRC method was developed both to check the radiochemical purity of [3H]-stobadine and to quantify the labeled drug in rat plasma. A spectrofluorometric approach was used for determination of stobadine in dog serum and urine after its administration in the form of either the dihydrochloride or the dipalmitate. The method allowed us to perform a bioavailability study and a long-term toxicological study. The HPLC method with a limit of detection of 10 ng/ml of plasma proved suitable for calculating the compartmental pharmacokinetic parameters of both salt forms of stobadine administered to dog and man. This method was based on solid-phase extraction procedure by using Separcol SI C18 cartridges. In a GC method, the combination of capillary column separation and nitrogen-specific detection permitted the assay of serum stobadine concentrations as low as 5 ng/ml. The detection limit of the GC/MS method was 1 ng/ml of plasma or of phosphate buffer saline. This method was used for a bioequivalence study of two stobadine dipalmitate dosage forms and for a transdermal penetration study of stobadine acyl derivatives. All the developed assays proved to be appropriate for low-concentration determination of stobadine in a wide range of pharmacokinetic studies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10716062     DOI: 10.1007/BF03190026

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  12 in total

1.  A high-performance liquid chromatographic method for the determination of stobadin pharmacokinetics in serum.

Authors:  L Soltés; Z Kállay; S Bezek; V Fedelesová
Journal:  Biopharm Drug Dispos       Date:  1991 Jan-Feb       Impact factor: 1.627

2.  Thin-layer chromatographic determination of 3H-labelled stobadin in rat plasma for pharmacokinetic purposes.

Authors:  J Bittererová; L Soltés; Z Kállay; T Trnovec
Journal:  Pharmazie       Date:  1990-06       Impact factor: 1.267

3.  Selective solid-phase extraction of basic drugs by C18-silica. Discussion of possible interactions.

Authors:  V Marko; L Soltés; I Novák
Journal:  J Pharm Biomed Anal       Date:  1990       Impact factor: 3.935

Review 4.  Antioxidant and pharmacodynamic effects of pyridoindole stobadine.

Authors:  L Horáková; S Stolc
Journal:  Gen Pharmacol       Date:  1998-05

5.  Polar interactions in solid-phase extraction of basic drugs by octadecylsilanized silica.

Authors:  V Marko; L Soltés; K Radová
Journal:  J Chromatogr Sci       Date:  1990-08       Impact factor: 1.618

6.  Pharmacokinetics of stobadin and of the sum of its metabolites in rats during repeated administration.

Authors:  Z Kállay; L Soltés; T Trnovec
Journal:  Biopharm Drug Dispos       Date:  1991-04       Impact factor: 1.627

7.  Determination of stobadine, a novel cardioprotective drug, using capillary gas chromatography with nitrogen--phosphorus detection after its selective solid-phase extraction from serum.

Authors:  V Marko
Journal:  J Chromatogr       Date:  1988-12-09

8.  Plasma concentration, tissue distribution and excretion of the prospective cardioprotective agent cis-(-)-2,3,4,4a,5,9b-hexahydro-2,8-dimethyl-1H-pyrido-[4,3-b]indole dihydrochloride in rats.

Authors:  Z Kállay; J Bittererová; A Brejcha; V Faberová; S Bezek; T Trnovec
Journal:  Arzneimittelforschung       Date:  1990-09

9.  Biotransformation of stobadine, a gamma-carboline antiarrhythmic and cardioprotective agent, in rat liver microsomes.

Authors:  M Stefek; L Benes; M Jergelová; V Scasnár; L Turi-Nagy; P Kocis
Journal:  Xenobiotica       Date:  1987-09       Impact factor: 1.908

10.  Spectrofluorometric analysis in biological fluids of the dihydrochloride of (-)-cis-2,8-dimethyl-2,3,4,4a,5,9b-hexahydro-1-H-pyrido[4,3b]indole (DH 1011), a prospective antiarrhythmic.

Authors:  V Marko
Journal:  Pharmazie       Date:  1985-03       Impact factor: 1.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.